TOKYO, December 14, 2022 /PRNewswire/ — Eisai Co., Ltd. (headquarters : TokyoCEO: Haruo Naito“Eisai”) announced today that Eisai and University of Washington School of Medicine Saint Louis have entered into a global research collaboration agreement aimed at creating potential new treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
University of Washington is a world leader in research into the prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations collaborate in research on Alzheimer’s disease. The Phase II/III Tau NexGen study conducted by the Dominantly Inherited Alzheimer’s Network (DIAN-TU) trials unit, led by the University School of Medicine, is exploring the safety, tolerability, Biomarkers and cognitive efficacy of Eisai’s anti-MTBR (microtubule-binding region) tau antibody E2814 for the treatment of dominantly inherited Alzheimer’s disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab (generic name, development code: BAN2401) was selected as the background anti-amyloid agent.
The collaboration strategically combines University of Washington scientists’ expertise in basic and clinical research on neurodegenerative diseases, such as dementia, with Eisai’s extensive experience in drug discovery and development. Using human biology, the goal is to create several new therapeutic candidates as well as to discover and identify biomarkers within the next five years. Eisai will have the option to develop and commercialize all compounds and biomarkers that meet certain criteria in terms of research and development stages. In the event that Eisai chooses to exercise the options, Eisai will pay University of Washington milestone payments and royalties on future sales of each licensed compound.
dr. Teiji KimuraPh.D., Academia and Industry Alliance Officer, Deep Human Biology Learning (DHBL) Office of Eisai, said, “Patients living with neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are struggling with critical unmet medical needs, which is why Neurology is a key therapeutic area for Eisai. By collaborating with world-renowned research institutions such as University of Washington in Saint LouisEisai is working to fill our human health care mission and provide potential new and targeted disease modifying therapies with the ultimate goal of achieving a world free of neurodegenerative diseases. »
Public Relations Department, Eisai Co., Ltd.
Eisai Inc. (USA)
Libby Holman 201-753-1945
[Notes to editors]
1. About University of Washington Medicine School
WashU Medicine is a world leader in academic medicine, including biomedical research, patient care, and educational programs with 2,700 faculty. Its National Institutes of Health (NIH) research funding portfolio is the fourth largest among U.S. medical schools, has grown 54% over the past five years, and with institutional investment, WashU Medicine has grown engage well beyond $1 billion annually to innovation and training in fundamental and clinical research. Its faculty practice is consistently ranked among the top five in the nation, with more than 1,790 faculty physicians practicing at more than 60 sites who also serve on the medical staff of BJC HealthCare’s Barnes-Jewish and St. Louis Children’s Hospitals. WashU Medicine has a rich history of MD/PhD training, recently dedicated $100 million scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in all medical subspecialties as well as physiotherapy, occupational therapy, audiology and communication sciences .
#EISAI #WASHINGTON #UNIVERSITY #SCHOOL #MEDICINE #LOUIS #SIGNED #GLOBAL #RESEARCH #COLLABORATION #AGREEMENT #CREATE #THERAPIES #NEURODEGENERATIVE #DISEASES